Thursday, January 12, 2012

Irisin, the finding of a new hormone targetable for metabolic disease

The finding of a new hormone is not an everyday event.
A paper in Nature shows how Irisin could be an excellent target for a pharmaceutical company in the rush for an effective anti-obesity drug. 
For sure what this new finding shown is that metabolism control is a very intricate system, in which the brain - body interaction is all still the be investigated

A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis:

Nature advance online publication 11 January 2012. doi:10.1038/nature10777

Authors: Pontus Boström, Jun Wu, Mark P. Jedrychowski, Anisha Korde, Li Ye, James C. Lo, Kyle A. Rasbach, Elisabeth Almer Boström, Jang Hyun Choi, Jonathan Z. Long, Shingo Kajimura, Maria Cristina Zingaretti, Birgitte F. Vind, Hua Tu, Saverio Cinti, Kurt Højlund, Steven P. Gygi & Bruce M. Spiegelman

Exercise benefits a variety of organ systems in mammals, and some of the best-recognized effects of exercise on muscle are mediated by the transcriptional co-activator PPAR-γ co-activator-1 α (PGC1-α). Here we show in mouse that PGC1-α expression in muscle stimulates an increase in expression of FNDC5, a membrane protein that is cleaved and secreted as a newly identified hormone, irisin. Irisin acts on white adipose cells in culture and in vivo to stimulate UCP1 expression and a broad program of brown-fat-like development. Irisin is induced with exercise in mice and humans, and mildly increased irisin levels in the blood cause an increase in energy expenditure in mice with no changes in movement or food intake. This results in improvements in obesity and glucose homeostasis. Irisin could be therapeutic for human metabolic disease and other disorders that are improved with exercise